Aura Biosciences, Inc. (AURA)
- Previous Close
7.08 - Open
7.13 - Bid 7.16 x 400
- Ask 7.26 x 400
- Day's Range
6.96 - 7.28 - 52 Week Range
5.99 - 13.50 - Volume
113,154 - Avg. Volume
182,804 - Market Cap (intraday)
357.422M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-1.93 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.80
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
www.aurabiosciences.comRecent News: AURA
Performance Overview: AURA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AURA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AURA
Valuation Measures
Market Cap
357.42M
Enterprise Value
150.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.58
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.80
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-22.18%
Return on Equity (ttm)
-36.26%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-76.41M
Diluted EPS (ttm)
-1.93
Balance Sheet and Cash Flow
Total Cash (mrq)
226.15M
Total Debt/Equity (mrq)
8.66%
Levered Free Cash Flow (ttm)
-39.34M
Research Analysis: AURA
Company Insights: AURA
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: AURA
Daily – Vickers Top Buyers & Sellers for 11/13/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/10/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 10/06/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.